| Multiple Sclerosis |
1 |
1 |
| Stem Cell Research and Therapy |
0 |
0.99 |
| Transplantation |
0 |
0.98 |
| Transplant Evaluation |
0 |
0.58 |
| Canada |
0 |
0.46 |
| Disability |
0 |
0.3 |
| Intensive Care Unit |
0 |
0.26 |
| Veno-Occlusive Hepatic Disease |
0 |
0.22 |
| Adverse Effects |
0 |
0.15 |
| Central Nervous System |
0 |
0.15 |
| Disease-Modifying Therapy |
0 |
0.15 |
| Liver |
0 |
0.15 |
| Match |
0 |
0.15 |
| Medical Innovations |
0 |
0.15 |
| Multiple Sclerosis Treatment |
0 |
0.15 |
| Relapsing Remitting Multiple Sclerosis |
0 |
0.15 |
| Serum Sickness |
0 |
0.15 |
| Washington |
0 |
0.15 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Neutropenia |
0 |
0.09 |
| Patient Safety |
0 |
0.09 |